^
    Apply
    Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP (NCT03562832)
    Phase 2
    Allarity Therapeutics
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    06/20/2018
    Primary completion :
    04/01/2024
    Completion :
    08/01/2024
    HER-2 • BRCA1
    |
    stenoparib (2X-121)
    An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (NCT01618136)
    Phase 1/2
    Eisai Limited
    Completed
    Last update posted :
    06/19/2023
    Initiation :
    01/01/2012
    Primary completion :
    07/01/2015
    Completion :
    07/01/2015
    HER-2 • ER • PGR • ATM
    |
    HER-2 negative
    |
    carboplatin • paclitaxel • temozolomide • stenoparib (2X-121)
    Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers (NCT02396433)
    Phase 1/2
    The University of Texas Health Science Center a...
    Withdrawn
    Last update posted :
    08/25/2015
    Initiation :
    04/01/2015
    Primary completion :
    04/01/2015
    Completion :
    04/01/2015
    BRCA1 • BRCA2 • PTEN • BRCA
    |
    PTEN deletion • BRCA mutation • High HRD score
    |
    carboplatin • Halaven (eribulin mesylate) • stenoparib (2X-121)